Cargando…
NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice
Molecular markers scalable for clinical use are critical for the development of effective treatments and the design of clinical trials. Here, we identify proteins in sera of patients and mouse models with Charcot-Marie-Tooth disease (CMT) with characteristics that make them suitable as biomarkers in...
Autores principales: | Jennings, Matthew J, Kagiava, Alexia, Vendredy, Leen, Spaulding, Emily L, Stavrou, Marina, Hathazi, Denisa, Grüneboom, Anika, De Winter, Vicky, Gess, Burkhard, Schara, Ulrike, Pogoryelova, Oksana, Lochmüller, Hanns, Borchers, Christoph H, Roos, Andreas, Burgess, Robert W, Timmerman, Vincent, Kleopa, Kleopas A, Horvath, Rita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679171/ https://www.ncbi.nlm.nih.gov/pubmed/35148379 http://dx.doi.org/10.1093/brain/awac055 |
Ejemplares similares
-
Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies
por: Stavrou, Marina, et al.
Publicado: (2021) -
Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease
por: Olympiou, Margarita, et al.
Publicado: (2016) -
Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy
por: Schiza, Natasa, et al.
Publicado: (2019) -
Transient, Recurrent Central Nervous System Clinical Manifestations of X-Linked Charcot-Marie-Tooth Disease Presenting with Very Long Latency Periods between Episodes: Is Prolonged Sun Exposure a Provoking Factor?
por: Tziakouri, Andria, et al.
Publicado: (2020) -
CMT1A current gene therapy approaches and promising biomarkers
por: Stavrou, Marina, et al.
Publicado: (2022)